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Simple Summary: In addition to cancer-related factors, anti-cancer chemotherapy treatment can
drive life-threatening body wasting in a syndrome known as cachexia. Emerging evidence has
described the impact of several key chemotherapeutic agents on skeletal muscle in particular, and
the mechanisms are gradually being unravelled. Despite this evidence, there remains very little
research regarding therapeutic strategies to protect muscle during anti-cancer treatment and current
global grand challenges focused on deciphering the cachexia conundrum fail to consider this aspect—
chemotherapy-induced myopathy remains very much on the dark side of the cachexia sphere. This
review explores the impact and mechanisms of, and current investigative strategies to protect against,
chemotherapy-induced myopathy to illuminate this serious issue.
Abstract: Cancer cachexia is a debilitating multi-factorial wasting syndrome characterised by severe
skeletal muscle wasting and dysfunction (i.e., myopathy). In the oncology setting, cachexia arises
from synergistic insults from both cancer–host interactions and chemotherapy-related toxicity. The
majority of studies have surrounded the cancer–host interaction side of cancer cachexia, often over-
looking the capability of chemotherapy to induce cachectic myopathy. Accumulating evidence in
experimental models of cachexia suggests that some chemotherapeutic agents rapidly induce cachec-
tic myopathy, although the underlying mechanisms responsible vary between agents. Importantly,
we highlight the capacity of specific chemotherapeutic agents to induce cachectic myopathy, as not
all chemotherapies have been evaluated for cachexia-inducing properties—alone or in clinically
compatible regimens. Furthermore, we discuss the experimental evidence surrounding therapeutic
strategies that have been evaluated in chemotherapy-induced cachexia models, with particular focus
on exercise interventions and adjuvant therapeutic candidates targeted at the mitochondria.
Keywords: cachexia; chemotherapy; exercise therapy; mitoprotection; muscle wasting; myopathy;
pharmaceutical adjuvants; skeletal muscle
1. Introduction
Chemotherapy constitutes a group of anti-neoplastic agents that were progressively
discovered throughout the 19th century and became commonplace in oncological treat-
ment as first-line or complementary therapeutic strategies for nearly all cancer types [1].
In general, chemotherapy targets cell cycle arrest through DNA-damage pathways that
promote apoptotic cell death, although agents are heterogeneously stratified into different
classes depending on their mode of action [2]. Independent of their different mechanisms,
chemotherapies remain effective at inducing cancer cytotoxicity to abate the hyper-active
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neoplastic cell cycle [3]. Despite exerting anti-cancer efficacy, chemotherapy also elicits
detrimental off-target side-effects to otherwise healthy cells due to their non-specific cy-
totoxicity [4]. Systemic toxicities are pervasive in the blood cell population as well as
the central and peripheral nervous, gastrointestinal, cardiovascular, and integumentary
systems [5–8]. Over the past decade, interest has developed concerning the non-specific im-
pact of chemotherapy-induced toxicity on the skeletal muscular system [9–11]. Specifically,
chemotherapeutic agents reduce body mass concurrent with skeletal muscle atrophy and
dysfunction (referred to herein, as cachectic myopathy). These side-effects are clinically
evident during patient deconditioning in the oncological setting [12], where weight loss
and fatigue are two key debilitating events prominent in metabolic wasting syndrome,
cachexia [13].
Cachexia is a multifactorial condition characterised by the loss of body mass and com-
position (highlighted by lean mass loss, with or without loss of fat mass) and progressive
functional impairment [14]. The centrally afflicted organ in cachexia is skeletal muscle,
which is driven by a multitude of factors including metabolic dysregulation; anorexia;
systemic inflammation; and insulin resistance [15]. Skeletal muscle mass is an integral
prognostic marker in cancer cachexia diagnosis—this is because increased adiposity de-
sensitises the utility of body weight and body mass index (a crude indicator of body compo-
sition) during cachexia diagnosis [16,17]. Once instigated, cachectic myopathy propagates
a vicious cycle involving increased risk of dose-related toxicities, which influences patient
risk stratification and clinical decision making [18]. The result is compromised treatment
efficacy (i.e., dose-reduction or treatment cessation) that increases the risk of morbidity
and mortality [18]. Cachectic myopathy is the result of two synergistic insults from each
of: (1) cancer–host interactions and (2) chemotherapy toxicity [15,19]. These effects can be
acute, yet are most often life-long [20]. While the number of studies concerning cachexia
is increasing exponentially, the proportion of these studies focusing on the impact of
chemotherapy is far behind [9].
Overall, cancer cachexia represents a significant burden on patients and clinicians,
with estimates suggesting that cachexia affects 50–80% of cancer patients and accounts
for up to 20% of cancer deaths [21]. There are no current treatment options outside of
standard nutrition interventions for body mass loss, which are largely unsuccessful [22,23].
Thus, cachexia is a significant unmet challenge in need of pre-clinical investigations to
identify novel drug-targets and evaluate therapeutic interventions for clinical translation.
Herein, we present a review of the literature surrounding experimental chemotherapy-
induced cachexia, with particular focus on the skeletal muscle-specific side-effects and
underlying mechanisms of myopathy. We also discuss the challenges associated with
current experimental approaches used to investigate chemotherapy-induced cachexia and
adjuvant strategies to protect against it.
2. Mechanisms of Chemotherapy-Induced Cachectic Myopathy
Chemotherapeutic agents work through different modes of action, which likely in-
fluences the degree to which they can induce cachectic myopathy. However, of the agents
that do induce myopathy, there are some common underlying mechanisms [9]. It has
been proposed that chemotherapy promotes systemic inflammation via the central nervous
system, specifically through stimulation of the hypothalamus–pituitary–adrenal axis, to
induce an adaptive illness response [24]. This response simultaneously induces the release
of glucocorticoids and the production of pro-inflammatory cytokines (e.g., interleukin-1α
and β, interleukin-6, and tumour necrosis factor-α (TNF-α)), which are both key events
in the induction of skeletal muscle atrophy [25,26]. In particular, over-production of
pro-inflammatory cytokines can directly induce skeletal muscle atrophy via engagement
of membranous receptors and activation of a pro-catabolic transcription program [9,13].
Braun et al. proposes that instigation of the inflammatory milieu caused by chemotherapy
increases activity of the gene, regulated in development and DNA damage response 1
(REDD1), which is associated with skeletal muscle atrophy [24]. REDD1 transcription
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regulates the adaptive stress response including the activation of stress-sensitive molecular
targets, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and mito-
gen activated protein kinase (MAPK) [27,28]. These two targets share common signalling
pathways during oxidant-induced stress [29]. In particular, MAPK activity promotes phos-
phorylation of the NF-κB subunit, p65, resulting in NF-κB activation and the induction
of skeletal muscle atrophy [29]. This atrophic response is achieved primarily through the
ubiquitin-proteasome system (UPS)-mediated transcription of classic atrogenes, the E3
ubiquitin ligases, MuRF-1, and Atrogin-1 [30,31]. Additionally, it has been demonstrated
by our laboratory and others that several chemotherapeutic agents can promote reactive
oxygen species (ROS) production in C2C12 myotubes, which is associated with impaired
myotube morphometry [32–35]. These data suggest that stress-sensitive molecular targets
could be common signalling pathways in chemotherapy-induced cachectic myopathy.
Furthermore, excessive ROS production is associated with the onset of mitochondrial dys-
function, an event postulated to be the crucial trigger for the induction of skeletal muscle
wasting by chemotherapy [36].
As well as through directly targeting differentiated skeletal muscle tissue, chemother-
apeutic agents also target myoprogenitor activity (i.e., satellite cell replication), which
impacts skeletal muscle growth, repair, and turnover (as reviewed by us previously [37]).
Many chemotherapeutic agents arrest cell cycling as their principal mechanisms of action
against rampant cancer cell proliferation, resulting in visible side-effects in high-turnover
cells including hair, bone marrow, skin, and gastrointestinal epithelium. It has recently
emerged that muscle satellite (stem) cells, which normally undergo rapid proliferation
and differentiation in response to muscle damage (e.g., inflammation) and growth factors
(e.g., growth hormone and androgens) are also impacted, contributing to the net loss of
muscle mass observed during cancer-related cachexia [38–40].
The research to date has predominantly focused on three key chemotherapeutic agents
to study the mechanisms that govern chemotherapy-induced cachectic myopathy: the
anthracycline, doxorubicin (DOX); the platinum-based alkylating agent, cisplatin (cis-
diamminedichloroplatinum(II) (CDDP)); and the anti-metabolite, 5-fluorouracil (5FU). As
such, we will further explore the current understanding of the connection between these
stress-signalling cascades and the induction of cachectic myopathy in the context of specific
chemotherapeutic agents and/or regimens.
2.1. Doxorubicin (DOX)
DOX is a member of the anthracycline class of chemotherapies, and, as such, it elic-
its cytotoxicity via topoisomerase-II inhibition to induce DNA damage and cell cycle
arrest [41]. Despite its potent anti-cancer efficacy, DOX is notorious for its cardiotoxic
properties, which significantly limits its clinical utility [42]. Subsequently, there has been
substantial interest in the effect of DOX on skeletal muscle health (summarised in Figure 1),
particularly since skeletal muscle is an active compartment in the metabolism of DOX
and its metabolites (e.g., DOX metabolite, doxorubicinol) is retained within skeletal mus-
cle tissue for up to five days post-intravenous delivery [43,44]. The clinical implications
of DOX administration are remarkable. Patients often present with debilitating fatigue,
muscle weakness, and impaired ambulatory capacity [45,46]. At the cellular level, DOX
treatment induces skeletal muscle dysfunction [47,48] characterised by reduced force pro-
duction, impaired calcium (Ca2+) dynamics, and increased susceptibility to physiological
fatigue [47–49]. Importantly, Gilliam et al. highlighted that these symptoms are dependent
on the activity of pro-inflammatory cytokine, TNF-α [50]. This pro-inflammatory scenario
has been shown to promote pyroptosis, a biological process of programmed cell death,
which is characterised by the nucleotide binding oligmerisation domain (NOD), leucine
rich repeat-containing proteins (NLR) family member, NRLP3 inflammasome formation,
and activation of apoptotic caspases [51,52]. Furthermore, TNF-α mediates skeletal muscle
contractile dysfunction through enhanced ROS production [53], although this is considered
to be an additive effect to DOX-induced oxidative stress. DOX can directly stimulate ROS
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production through redox cycling at NADH dehydrogenase/Complex I of the mitochon-
drial electron transport chain [54]. As a result, ROS are produced, in particular superoxide
anion radicals, via the reduction of DOX’s quinone moiety to an unstable semiquinone [54].
This redox cycling significantly elevates skeletal muscle hydrogen peroxide (H2O2) emis-
sion without perturbing homeostatic antioxidant buffering capacity [55–57] and alters
bioenergetic efficiency by impinging on the functionality of respiratory complexes, leading
to modifications that promote oxidative damage (e.g., lipid peroxidation) [56,58]. Recent
findings from the Hulmi group suggest that DOX-induced skeletal muscle perturbations
are predominately influenced by enhanced transcription of REDD1 as part of the tran-
scriptional program regulated by oxidative stress sensitive tumour suppressor protein,
p53, a master regulator of cellular homeostasis [59–61]. Interestingly, there are few data
connecting the promotion of inflammatory cytokines and oxidative stress from DOX to
increased NF-κB activity in skeletal muscle, which is a downstream target of REDD1 tran-
scription. Supriya et al. showed that DOX potentiated NF-κB activity in the skeletal muscle
of diabetic mice [62]. The authors suggested that several mechanisms downstream of
REDD1 were likely contributing [62].
Enhanced oxidative damage from DOX administration induces modifications that
increase the catabolism of myofibrillar proteins, in particular actin and myosin, two in-
tegral proteins of the contractile apparatus [33,63]. The pro-catabolic signalling-cascade
potentiated by DOX can activate multiple proteolytic systems including the UPS, au-
tophagy, apoptotic caspases, and Ca2+-dependent proteases (i.e., calpains) [56,63,64]. The
pro-catabolic shift in skeletal muscle protein balance has led to the consensus that DOX
can cause skeletal muscle mass loss [11]. While DOX mechanisms are largely centred
around proteolysis, there is also a rationale to suggest DOX impairs anabolism. This is
highlighted by a reduced rate of protein synthesis independent of the classical signalling
of mechanistic target of rapamycin complex 1 (mTORC1) [59], a key mediator of protein
synthesis (for extensive review see [65]). There is also some evidence that DOX admin-
istration can impair the regenerative capacity of muscle through inhibiting satellite cell
proliferation [66]. These data implicate alternative pathways that regulate protein synthesis
during DOX administration. One such pathway was the activation of the endoplasmic retic-
ulum stress/unfolded protein response signalling cascade, which can negatively regulate
protein synthesis [67]. However, there were divergent responses between different types of
striated muscle (i.e., heart, diaphragm, and limb skeletal muscles) and the expression of
markers involved in this signalling cascade, elicited by DOX [55,68]. Thus, further research
is required to enrich the understanding of the processes regulating the skeletal muscle
protein balance during DOX treatment.
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Figure 1. Known mechanisms of doxorubicin (DOX)-induced cachectic myopathy. DOX promotes 
reactive oxygen species (ROS) production primarily via Complex I dysfunction, which induces 
mitochondrial dysfunction and tumour-necrosis factor-α (TNF-α)-dependent inflammation, which 
can promote pyroptosis via increased nucleotide binding oligmerisation domain, leucine rich re-
peat-containing protein 3 (NLRP3) inflammasome formation, and activation of apoptotic caspases. 
This stimulates a regulation in the development and DNA damage response 1 (REDD1) transcrip-
tion program, which overarches DOX-induced cachectic myopathy. DOX also reduces the replen-
ishment of the satellite cell pool, which contributes to cachectic myopathy through impaired mus-
cle repair. Underlying skeletal muscle wasting, DOX increases protein degradation via the ubiqui-
tin-proteasomal system (UPS), autophagy, apoptotic caspases, and the calcium (Ca2+)-dependent 
proteases, calpains, while also reducing protein synthesis in a mammalian target of rapamycin 
complex 1 (mTORC1)-independent manner. While the exact mechanism has not been fully eluci-
dated, endoplasmic reticulum (ER) stress or the unfolded protein response (UPR) signalling may 
be contributing factors. DOX also alters Ca2+ dynamics and promotes oxidative damage to myofi-
brillar proteins causing skeletal muscle dysfunction. Created with biorender.com (accessed on 6 
July 2021). 
2.2. Cisplatin (CDDP) 
CDDP is a platinum-based alkylating agent that enhances DNA damage via the aqua-
tion of its chloride ligands to form a highly reactive mono-aquated complex. This complex 
Figure 1. Known mechanisms of doxorubicin (DOX)-induced cachectic myopathy. DOX promotes
reactive oxygen species (ROS) production primarily via Complex I dysfunction, which induces
mitochondrial dysfunction and tumour-necrosis factor-α (TNF-α)-dependent inflammation, which
can promote pyroptosis via increased nucleotide binding oligmerisation domain, leucine rich repeat-
containing protein 3 (NLRP3) inflammasome formation, and activation of apoptotic caspases. This
stimulates a regulatio in the developme t and DNA damage response 1 (RED 1) transcription
program, which overarches DOX-induced cachectic myopathy. DOX also reduces the replenishment
of the satellite cell pool, which contributes to cachectic myopathy through impaired muscle repair. Un-
derlying skeletal muscle wasting, DOX increases protein degradation via the ubiquitin-proteasomal
system (UPS), autophagy, apoptotic caspases, and the calcium (Ca2+)-dependent proteases, calpains,
while also reducing protein synthesis in a mammalian target of rapamycin complex 1 (mTORC1)-
independent manner. While the exact mechanism has not been fully elucidated, endoplasmic
reticulum (ER) stress or the unfolded protein response (UPR) signalling may be contributing factors.
DOX also alters Ca2+ dynamics and promotes oxid tive damage to myofibrillar proteins causing
sk letal muscle dysfunction. Created with b orender.com ( ccessed on 6 July 2021).
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2.2. Cisplatin (CDDP)
CDDP is a platinum-based alkylating agent that enhances DNA damage via the
aquation of its chloride ligands to form a highly reactive mono-aquated complex. This
complex can bind with DNA residues to develop CDDP-DNA adducts, which induce DNA
crosslinking and cell cycle arrest [69]. CDDP administration is associated with several
toxicities, notably nephrotoxicity and neurotoxicity [70,71]. However, it also has deleterious
impact on skeletal muscle (critically reviewed in detail previously [10,72]). CDDP was orig-
inally considered a potent inducer of negative protein balance—predominantly through
impacting caloric intake (i.e., food consumption), which drives protein degradation to re-
duce body and skeletal muscle mass [73] (Figure 2). Importantly, Sakai et al. demonstrated
that CDDP can drive protein degradation independently of caloric intake (through using
pair-fed controls), in part, via an Akt and forkhead box O (FoxO)-dependent signalling
cascade that enhances the transcription of atrogenes MuRF-1 and Atrogin-1 [74] while
synergistically activating other constituents of the UPS [75]. CDDP also promotes the accu-
mulation of autophagosomes (an indicator of autophagy-lysosome system dysregulation)
via a similar, although currently undefined, Akt/FoxO3a-dependent mechanism [34,76,77].
Furthermore, CDDP suppresses protein synthesis via a protein kinase B (Akt)-dependent
mechanism, which leads to the de-phosphorylation of p70S6k1, a downstream target of
mTORC1 [78]. Thus, muscle anabolism signalling also appears to be impacted by CDDP
(Figure 2). Damreuer et al. demonstrated that CDDP-mediated atrogene transcription
occurs in response to trans-activation of NF-κB, specifically through the heterodimerisa-
tion of key subunit proteins, p50 and p65 [79]. Enhanced proteolysis induced by CDDP
underscores skeletal muscle wasting, and this was initially thought to be the driver of
functional decline [80]. However, recent findings from Conte et al. demonstrate that CDDP
also dysregulates Ca2+ ion homeostasis, which is necessary for optimal skeletal muscle
function [81]. CDDP increases the intracellular concentration of Ca2+, compromises Ca2+
dynamics, and de-sensitises the excitability of action potentials, resulting in reduced force
production [82]. CDDP-induced oxidative stress is also thought to contribute to a dysfunc-
tional contractile apparatus, although the underlying mechanisms are presently unclear.
Sirago et al. proposed that CDDP drives H2O2 production and oxidative stress based
upon evidence of increased peroxiredoxin (PRX) sulphonylation in skeletal muscle [77,83],
which is also central to CDDP’s anti-cancer properties [84]. This mechanism has fascinating
potential for therapeutic intervention given that PRX suppression is a key stimulant for
NF-κB trans-activation [85], a critical target for CDDP-induced myopathy [9].
While CDDP is the predominate platinum-based chemotherapeutic agent experimen-
tally evaluated for its effect on skeletal muscle health, our laboratory and others have
demonstrated that analogues, carboplatin [86,87] and oxaliplatin (OXA) [88–90] can also
contribute to the induction of cachectic myopathy. A complicating factor in the research sur-
rounding platinum-based agents is the reliance on solvent, dimethyl sulphoxide (DMSO),
to prepare experimental drug solutions. Using DMSO to deliver the chemotherapeutic
agents CDDP and carboplatin suppresses their relative cytotoxicity in cell culture, whereas
the cytotoxicity elicited by OXA is not impacted [91,92]. This highlights the complexity of
interpreting the experimental data surrounding platinum-based complexes in comparison
to vehicle control groups that do not disclose information regarding DMSO utilisation, an
all too common feature in the accumulated literature thus far [92].
Cancers 2021, 13, 3615 7 of 27Cancers 2021, 13, x 7 of 27  
 
 
Figure 2. Known mechanisms of cisplatin (cis-diamminedichloropaltinum(II) (CDDP))-induced 
cachectic myopathy. CDDP promotes reactive oxygen species (ROS) production potentially 
through: (1) increased peroxiredoxin (PRX) sulphonylation; and (2) inflammation induced by pro-
inflammatory cytokine mediated nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) transcription program activation, which is a central mechanism of CDDP-induced cachec-
tic myopathy. The underlying mechanism regulating CDDP-induced skeletal muscle wasting is 
increased protein degradation involving elevated ubiquitin-proteasomal system (UPS) activity and 
the promotion of macroautophagy. Additionally, there is evidence of reduced protein synthesis 
via mammalian target of rapamycin complex 1 (mTORC1)-dependent signalling cascades. CDDP 
induces skeletal muscle dysfunction through promoting aberrant calcium (Ca2+) dynamics and 
oxidative damage to myofibrillar proteins. Created with biorender.com (accessed on 6 July 2021). 
2.3. 5-Fluorouracil (5FU) 
5FU is a chemotherapeutic agent from the anti-metabolite class that elicits cytotoxi-
city via: (1) the misincorporation of nucleotides into RNA and DNA; and (2) the inhibition 
of the nucleotide enzyme, thymidylate synthase. This leads to both DNA and RNA dam-
age and cell cycle arrest [93]. 5FU is primarily utilised against colorectal cancer as a back-
bone constituent of multi-agent regimens. However, it can elicit debilitating side-effects 
independently [93], emphasised by gastrointestinal toxicities such as mucositis and en-
teric neuropathy [94–96]. With respect to the side-effects of 5FU on skeletal muscle, there 
is mixed evidence as to whether it can independently drive the loss of mass and function 
[97–99]. Interestingly, VanderVeen et al. demonstrated that 5FU administration impairs 
the homeostatic coordination of skeletal muscle repair and remodelling through reducing 
M1-like macrophage abundance [98]. This suggests that 5FU dysregulates monocyte re-
cruitment and drives a shift towards a pro-fibrotic skeletal muscle microenvironment [98] 
(Figure 3). The Bonetto group have extensively demonstrated that the 5FU-based combi-
nation regimen, FOLFIRI [5FU, leucovorin (LV), and irinotecan (IRI)], can drive cachectic 
Figure 2. Known mechanisms of cisplatin (cis-diamminedichloropaltinum(II) (CDDP))-induced
cachectic myopathy. CDDP promotes reactive oxygen species (ROS) production potentially through:
(1) increased peroxiredoxin (PRX) sulphonylation; and (2) inflammation induced by pro-inflammatory
cytokine mediated nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) transcrip-
tion program activation, which is a central mechanis of CDDP-induced cachectic myopathy. The
underlying mechanism regul ting CDDP-induced skeletal muscle wasting is increased protein
degradation involving elevated ubiquitin-proteasomal system (UPS) activity and the promotion
of macroautophagy. Additionally, there is evidence of reduced protein synthesis via mammalian
target of rapamycin complex 1 (mTORC1)-dependent signalling cascades. CDDP induces skeletal
muscle dysfunction through promoting b rrant calcium (Ca2+) dynamics and oxidative damage to
myofibrillar proteins. Created with biorender.com (accessed on 6 July 2021).
2.3. 5-Fluorouracil (5FU)
5FU is a chemotherapeutic ag nt from the anti-metabolite class t at elicits cytotoxicity
via: (1) the misincorporation of nucleotides into RNA and DNA; (2) the inhibition of
the nucleotide enzyme, thymidylate synthase. This leads to both DNA and RNA damage
and cell cycle arres [93]. 5FU is primarily ut lised against colorectal canc r as a back-
bone constituent of multi-agent regimens. However, it can elicit debilitating side-effects
independently [93], emphasised by gastrointestinal toxicities such as mucositis and en-
teric neuropathy [94–96]. With respect to the side-effects of 5FU on skeletal muscle, there
is mixed evidence as to whether it can independently drive the loss of mass and func-
tion [97–99]. Interestingly, VanderVeen et al. demonstrated that 5FU administration impairs
the homeostatic coordination of skeletal muscle repair and remodelling through reducing
M1-like macrophage abundance [98]. This suggests that 5FU dysregulates monocyte re-
cruitment and drives a shift towards a pro-fibrotic skeletal muscle microenvironment [98]
(Figure 3). The Bonetto group have extensively demonstrated that the 5FU-based combi-
nation regimen, FOLFIRI [5FU, leucovorin (LV), and irinotecan (IRI)], can drive cachectic
myopathy, with several mechanisms explored [35,100–103]. In skeletal muscle, FOLFIRI:
(1) promotes the phosphorylation of MAPK isoforms, p38 and ERK1/2; (2) increases serum
ROS levels; (3) reduces mitochondrial number and size; and (4) downregulates the ex-
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pression of protein markers indicative of mitochondrial maintenance and turnover (i.e.,
biogenesis, fission, and fusion) [35,101,102]. Despite FOLFIRI inducing cachectic myopathy,
the 5FU-based combination regimen FOLFOX [5FU, LV, and OXA] has limited impact on
skeletal muscle [35]. While these data may be accounted for by methodological specifics
concerning the treatment timeline and/or dosages of the FOLFOX constituents, it is an
interesting observation when considered in context of findings from our laboratory. We
have demonstrated that IRI (constituent of the FOLFIRI regimen) monotherapy induces
cachectic myopathy [104], which is characterised by reduced expression of dystrophin, a
key structural protein that connects the sarcolemma to the actin cytoskeleton and maintains
cytoskeletal integrity [104]. Similarly, we recently demonstrated that 5FU monotherapy
also reduces dystrophin protein expression, in addition to desmin, an intermediate filament
that provides stability to sarcomeres. However, these cytoskeletal protein changes are
not associated with overt cachectic myopathy or loss of function [99]. These findings
highlight that: (1) 5FU may prime skeletal muscle for myopathy by reducing the abun-
dance of key cytoskeletal structural proteins; and (2) these events (i.e., loss of dystrophin
and other cytoskeletal proteins) apparently precede alterations to skeletal muscle mass or
function (Figure 3). Our work suggests that cytoskeletal proteins may have potential as
early biomarkers for chemotherapy-induced cachectic myopathy, although this requires
further investigation to be confirmed.
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Figure 3. (5FU)-related cachectic myopathy. 5FU monotherapy promotes the phosphorylation of
atrophic regulators, p38 mitogen activated protein kinase (MAPK), and nuclear factor kappa-light-chain-
enhancer of activated B cells ( F-κB). These mechanistic targets are likely to be stimulated via signalling
modulators including reactive oxygen species (ROS). 5FU does induce a pro-fibrotic skeletal muscle
microenvironment and reduces the expression of the key cytoskeletal proteins, desmin and dystrophin,
hich suggests that 5FU primes muscle for cachectic myopathy. Interestingly, when additional chemo-
toxic insult to skeletal m scle occurs alongside 5FU such as in 5FU combi ation regimens, the induction
of cachectic myopathy is observed. This is underscored by increased ROS production that stimulates the
phosphorylation of p38 MAPK and ERK1/2 alongside mitochondrial dysfunction, leading to skeletal
muscle wasting and dysfunction. Created with biorender.com (accessed on 6 July 2021).
2.4. Other Chemotherapeutic Agents
Several other chemotherapeutic agents have been investigated for their impact on
skeletal muscle, albeit to a far lesser extent than DOX, CDDP, and 5FU. Distinct from
platinum-based alkylating agents, chemotherapies arising from the alternative alkylat-
ing agent classes such as nitrosourea (i.e., cystemustine (CMN)) and nitrogen mustard
(i.e., cyclophosphamide (CYP)) have also been investigated for their effect on skeletal
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muscle [73,105–107]. Interestingly, in cancer-free mice, CMN acutely reduces body mass,
and, while post-chemotherapy catch-up growth is evident, skeletal muscle mass does not
completely recover [106]. However, in tumour-bearing mice, the effect of CMN manifests
differently. CMN treatment (10 days) reduces skeletal muscle mass, albeit, paradoxically,
concurrent with enhanced protein synthesis and reduced proteasome-dependent proteoly-
sis at the molecular level [105,106]. These data perhaps reflect an ongoing, yet unsuccessful,
attempt to recover skeletal muscle mass in response to CMN treatment. Similar to CMN,
CYP administration induces an acute loss of body mass followed by compensatory catch-up
growth in cancer-free mice, but skeletal muscle mass loss is only mildly impacted [107].
However, CYP reduces ambulatory capacity and skeletal muscle adenosine triphosphate
(ATP) production through impairing mitochondrial function [107]. CYP may also impact
skeletal muscle through inducing neutropenia (CYP is used experimentally to generate
rodent models of neutropenia) [108], possibly through impacting skeletal muscle repair
and remodelling efficiency. A similar effect has been reported for 5FU [98].
Gemcitabine (GCB) is a chemotherapeutic agent from the anti-metabolite class, which
has often been experimentally investigated as part of a combination regimen with CDDP
consistent with its clinical utility for the treatment of metastatic cancers [109–111]. Given the
extensive evidence supporting that CDDP treatment induces cachectic myopathy [10,72],
it is currently unclear as to what extent (if at all) GCB contributes. Current evidence
demonstrates that the CDDP and GCB combination potentiates tumour-induced skeletal
muscle mass loss and proteolytic activity, while GCB alone has no impact [112–114]. This
does not rule out the possibility that GCB exacerbates the effects of CDDP in skeletal
muscle. Another chemotherapeutic agent from the anti-metabolite class is methotrexate
(MTX), which is not only utilised in cancer, but in hyper-inflammatory conditions such as
rheumatoid arthritis [115]. There are no data available surrounding the effect of MTX on
skeletal muscle health in cancer-based models. However, in a mouse model of diabetes,
MTX was shown to elicit benefits on skeletal muscle glucose metabolism [116,117]. These
findings suggest that chemotherapeutic agents from the anti-metabolite class display a
modest myotoxic profile compared to other chemotherapy classes.
Mitotic inhibitors are a class of chemotherapeutic agents that have been investigated
for their effect on skeletal muscle, in particular taxanes and vinca alkaloids [118]. These
drugs are known for their microtubule de-stabilising properties and potent neurotoxic-
ity [119–121]. Docetaxel (DTX) is a taxane-based chemotherapy that demonstrably reduces
skeletal muscle mass. This effect is evidenced by serum markers of malnutrition and
inflammation, and a pro-catabolic transcriptional program, yet skeletal muscle contractile
function is not affected [122,123]. Paclitaxel (PTX) is another taxane-based agent, albeit not
extensively investigated with respect to skeletal muscle. Ramos et al. highlighted the ca-
pacity of PTX to alter skeletal muscle microtubule architecture observed through α-tubulin
disorganisation [118]. Additionally, alterations to microtubules by PTX are suggested to be
underpinned by impaired adenosine diphosphate (ADP)-dependent bioenergetics via the
binding of tubulin to the mitochondrial ADP/ATP exchanger voltage-dependent anion
channel (VDAC) [118]. Ramos et al. also studied the vinca alkaloid, vinblastine (VBL),
and demonstrated a similar capacity to alter tubulin architecture. However, distinct from
PTX, the connection with impaired ADP bioenergetics is seemingly independent of the
interaction between tubulin and VDAC [118]. Rather, the mechanism may be reflective of
the lesser-known role of VBL as an inhibitor of microtubule-associated proteins, 1A/1B
light chain 3B (LC3B)-II, degradation. Thus, VBL is a likely suppressor of auto-lysosomal
maturation and autophagic flux [124]. Further investigation of taxanes and vinca alkaloids
with regard to skeletal muscle health is warranted, given the association with microtubule
perturbations and induction of dystrophic phenotypes [125].
3. Therapeutic Strategies to Mitigate Chemotherapy-Induced Cachectic s Myopathy:
An Update
Currently, cachexia represents a significant unmet challenge in cancer, with no treat-
ment approved for clinical use. This is likely due to the complexity of the syndrome,
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especially at the skeletal muscle level. There are multiple contributing factors to the in-
duction of myopathy during anti-cancer therapy. For example, muscle deconditioning
due to hospitalisation-dependent factors such as prolonged periods of bed rest, reduced
opportunity to undertake physical activity, and depressive mood/fatigue could contribute
significantly to cachexia progression during chemotherapy administration [126]. Several in-
vestigations into therapeutic strategies to mitigate the debilitating effects of cancer cachexia
are underway with multiple candidates showing promise. These include exercise and multi-
target pharmaceutical/nutraceutical adjuvant interventions [127,128] (Figure 4). Herein,
we summarise the current knowledge and provide insights surrounding these candidate
strategies to better inform future investigations. In particular, this section will focus on
therapeutic strategies that elicit protection against mitochondrial dysfunction, a key mech-
anistic event in the induction of cachectic myopathy [129,130]. Specifically, mitochondrial
degeneration is suggested as an event preceding muscle wasting in cachexia [131], and
thus is a prime therapeutic target for early intervention.
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interventions. Broadly, chemotherapeutic agents used in clinical cancer treatment can both directly and indirectly target
skeletal muscle through induction or amplification of systemic cachexia. The result is the initiation of a wasting and
dysfunction program within skeletal muscle, involving: increased muscle protein degradation, reduced protein synthesis,
mitochondrial dysfunction and oxidative stress, cytoskeletal disorganisation and reduction of key cytoskeletal proteins
that stabilise the muscle membrane, pro-fibrotic signalling within the extracellular matrix, and altered calcium (Ca2+)
dynamics. The result is muscle wasting and dysfunction that leaves patients weak and fatigued, which affects their capacity
to undertake activities of daily living and reduces quality of life. Several potential therapeutic approaches are currently being
investigated to protect against or treat these symptoms including appetite stimulants, activin receptor signalling inhibitors,
nutritional supplements, and phytotherapies. Novel therapeutic strategies could include exercise and mitoprotective
compounds (e.g., SS-31, BGP-15, dimethyl fumarate (DMF), epicatechin, and pterostilbene). Abbreviations: CNS AIR:
central nervous system acute illness response. Created with biorender.com (accessed on 6 July 2021).
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3.1. Exercise Interventions
Exercise is a non-pharmacological and cost-effective strategy that is currently being
investigated for therapeutic purposes against cachexia. The therapeutic potential of ex-
ercise in the cancer setting is multi-faceted, but includes both modulation of systemic
inflammation and regulatory control of the redox balance [130], two inherently related
mechanisms that drive cachexia [129]. These mechanisms are also prominent drivers of
chemotherapy-induced cachectic myopathy. Thus, exercise interventions could prevent the
atrophy and loss of function associated with anti-cancer chemotherapy treatment. As such,
exercise has been investigated in experimental models exploring its efficacy to mitigate
the impact of chemotherapy (particularly DOX) on skeletal muscle health (summarised
in Table 1). In general, exercise has shown modest protective efficacy against the loss of
skeletal muscle mass and functionality from chemotherapy administration [132]. Smuder
proposes that this is linked to the capacity of exercise to promote endogenous antioxidant
expression, protein chaperoning via heat shock protein-70 (HSP-70) to mitigate proteolytic
activity, and increased multi-drug resistant proteins [133]. It is important to note that the
majority of studies listed in Table 1 employed exercise as a pre-conditioning strategy prior
to the administration of DOX, demonstrating the capacity of exercise to prime skeletal
muscle to resist DOX-induced stress [63,64,134–138]. However, the clinical compatibility
of this approach is questionable since cancer treatment would need to be delayed while
muscles were conditioned using exercise programs. There is also a lack of data on the
efficacy of pre-treatment exercise strategies for other chemotherapeutic agents aside from
DOX. Jones and Alfano highlight a paucity of clinical studies investigating the utility
of exercise interventions in the pre-treatment stage [139]. Rather, exercise interventions
throughout the cancer survivorship continuum have predominantly been studied dur-
ing and post-chemotherapy treatment, as per the adapted Physical Exercise Across the
Cancer Experience (PEACE) framework [139]. To date, only four pre-clinical studies have
investigated the efficacy of exercise during chemotherapy administration. These studies
investigated different chemotherapeutic agents and/or regimens as well as diverse exercise
modalities [78,140–142]. This makes it difficult to form a consensus sufficient to facilitate
clinical exercise prescription based upon pre-clinical data. For example, some studies
employed a maximal treadmill running test to exhaustion [141,143]. This is a low-cost
alternative to incorporating the use of metabolic studies that enable the quantification of
peak/maximum oxygen consumption (VO2 peak/max), which can be used to identify
a relative exercise intensity [144]. Other studies have incorporated metabolic analyses
enabling calculation of a relative VO2 peak/max [144]. However, given the lack of con-
sistency across different rodent models, a knowledge gap remains in translating exercise
intensity criteria between rodents and humans [145]. Additionally, there are no known
experimental studies assessing the utility of exercise in the post-treatment recovery stage.
Thus far, animal experiments investigating the utility of exercise programs to resist
chemotherapy-induced cachectic myopathy have not been without their pitfalls. There are
numerous confounding variables highlighted in Table 1 including the selection of rodent
species, strain, age, gender, and muscle type. These are all factors that can influence the
protective efficacy of exercise in the context of chemotherapy-induced myopathy [145–149].
Additionally, tissue harvest time, relative to final chemotherapy dose, is a crucial consider-
ation since transient events versus adaptive responses can be confused when making static
measurements at a fixed timepoint. It is also imperative for experimental models to evalu-
ate the feasibility and efficacy of resistance training during chemotherapy administration,
since in vivo load-induced hypertrophy has emerged as having translational potential (for
review see [150]). Animal studies to date have predominately focused on endurance train-
ing. In particular, it would be of great interest to determine whether chemotherapy-treated
skeletal muscle could recover from the myotrauma induced by resistance training inter-
ventions. Indeed, Huang et al. [151] demonstrates that DOX can impair the inflammatory
response necessary for skeletal muscle repair and remodelling following damaged caused
by eccentric-exercise. Thus, further investigation is warranted.
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Experimental animal models used to investigate the efficacy of exercise interventions
during the administration of chemotherapy often utilise a treatment regimen that involves
the metronomic delivery of chemotherapeutic agents spread out over an extended dura-
tion. This approach, while clinically compatible, results in milder skeletal muscle effects
compared to the pre-conditioning studies, which utilise a single near-maximum tolerable
dosage (MTD) bolus injection of a clinically-relevant accumulated human dose [152]. How-
ever, metronomic delivery of chemotherapy is a more compatible representation of the
clinical scenario. This is especially true for DOX, which is clinically administered through
slow-intravenous infusion or as repeated fractional doses cyclically over several weeks,
to regulate plasma concentration of the drug. As such, severe cytotoxicity is prevented
while anti-cancer efficacy is maintained [153]. The utility of metronomic delivery regimens
in experimental models of chemotherapy cachexia still require a balance between retain-
ing a clinically compatible cumulative dose and maintaining survival of the animals, so
that exercise training interventions can be implemented. Going forward, future studies
should refer to current gold standard models published in both de Lima et al. [143] and
Ballaro et al. [89], which evaluate the effect of exercise during the synergistic-induction
of cachectic myopathy from both chemotherapy and cancer-related factors. If possible, a
chemotherapy control group should be included alongside a cancer control group when
models are being optimised. This would help inform decision making regarding choice of
exercise modality and secondary targets outside of mass and function preservation (e.g.,
mitigating systemic inflammation or insulin resistance) [50,154,155]. Current models need
to be improved to enrich the clinical interpretability of the findings, thus promoting wider
translational capability.
Current clinical studies indicate that aerobic exercise training can reduce fatigue and
anxiety/depressive moods to improve participation in physical activity, while resistance
exercise training can improve lean mass and muscular strength [156–158]. Interestingly,
there is only weak evidence that either exercise modality can preserve skeletal muscle
mass or cross-sectional area (CSA) [156,159,160]. This may reflect difficulties associated
with measuring muscle mass in humans [161] or the barriers associated with incorporat-
ing muscle biopsies in clinical trials such as high costs and low patient recruitment due
to the invasiveness of sampling. Nevertheless, these data highlight inconsistency with
data derived from chemotherapy treated, cancer-free mouse models, which demonstrate
protective efficacy from exercise (see Table 1) [78,142]. Perhaps even more interesting,
and consistent with the clinical data, is that exercise did not alter skeletal muscle mass or
CSA in two tumour-burdened mouse models treated with chemotherapy [89,143]. Thus,
tumour factors appear to be most influential in dictating whether skeletal muscle can be
modulated by exercise. While mass may not necessarily be modifiable by exercise therapy,
de Lima et al. importantly demonstrated that exercise training improved skeletal muscle
recovery after the cessation of chemotherapy, a paradigm yet to be explored in clinical
studies [143]. Considering that current exercise interventions only elicit modest protective
efficacy against chemotherapy and cancer-induced cachectic myopathy at best, there is an
emphasis to explore multi-modal therapeutic strategies that involve exercise prescription
programs alongside pharmacological interventions for synergistic benefits. Furthermore,
given that some cancer patients may have a reduced opportunity to undertake exercise
training due to hospitalisation-related deconditioning, multi-targeted pharmacological
and/or supplementary interventions strategies that mimic specific aspects of exercise
should be identified and explored for their therapeutic efficacy.
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Table 1. Experimental studies on the effect of exercise against chemotherapy-induced cachectic myopathy.





TR: F: 5 days; I: 30 m/min; D: 60 mins/day; T:
0◦ incline.
1 × IPI 20 mg/kg of DOX
post-exercise. Harvest 24 h post-IPI.
TR normalised oxidative stress and damage,






TR: F: 5 days; I: 30 m/min; D: 60 mins/day; T:
0◦ incline.
1 × IPI 20 mg/kg of DOX
post-exercise. Harvest 24 h post-IPI.






1. TR with progressive overload: F: 5
days/week, for 10 weeks; I: 20 to 30 m/min; D:
20 to 60 min/day; T: incline 0 to 18◦.
2. CHL: Progressive food and water elevation
to stimulate voluntary bi-pedal standing or
jumping [162].
1 × IPI 15 mg/kg of DOX
post-exercise. Harvest 5 days
post-IPI.
TR was not protective against body mass loss
and exacerbated EDL muscle mass loss.
RT did not alter body or skeletal muscle mass but





TR: F: 5 days; I: 30 m/min; D: 60 mins/day; T:
0◦ incline.
1 × IPI 20 mg/kg of DOX
post-exercise. Harvest 24 h post-IPI.






TR: F: 5 days; I: 70% of maximal speed; D: 60
mins/day; T: 0◦ incline.
1 × IPI 15 mg/kg of DOX
post-exercise. Harvest 72 h post-IPI.
TR partially mitigated body mass loss. TR did





TR: F: 10 days; I: 30 m/min; D: 60 mins/day; T:
0◦ incline.
1 × IPI 20 mg/kg of DOX
post-exercise. Harvest 48 h post-IPI.
TR normalised DIA CSA, oxidative stress and





TR: F: 5 days/week, for 2 weeks; I: 30 m/min;
D: 60 mins/day; T: 0◦ incline.
1 × IPI 20 mg/kg of DOX
post-exercise. Harvest 48 h post-IPI.
TR normalised SOL dysfunction and the







TR with progressive overload: F: 5 days/week,
for 7 weeks, starting 1-week pre-IPI and
finishing 5 days post-IPI; I: 20 to 25 m/min; D:
30–40 min/day; T: 0 to 10◦ incline.
1 × IPI every 2 weeks, for 4 weeks
of 4 mg/kg DOX. Harvested 5 days
post-IPI.
Normalised REDD1 expression. No effect on
body mass or SOL muscle mass.




TR: F: 5 days/week, for 6 weeks; I: 60% of
maximal speed D: 60 mins/day; T: 0◦ incline.
2 × IPI per week for 6 weeks of 2.5
mg/kg DOX. Harvest not described
relative to final IPI.
TR did not mitigate glucose intolerance, reduced
body or GSN mass or protein synthesis.
However, TR normalised corticosterone levels,






VWR: VEH: 60–80 km/mouse/week; CDDP:
10–50 km/mouse/week.
1 × IPI per week of 4 mg/kg CDDP
for 6 weeks. Harvest 7 days post
final-IPI.
VWR partially mitigated the loss of lean and TA
mass and reduced atrogene expression. Did not
protect against body or fat mass loss.




TR: F: once a day for 9 days–5 days/week
pre-CDDP and 4 days/week during CDDP
week; I: 15 m/min; D: 20 min/day; T: 0◦ incline.
1 × IPI 3 mg/kg CDDP daily for 4
days. Harvest 24 h post-IPI.
TR did not alter body mass loss, but partially
normalised QD mass and CSA, and atrogene
expression.
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Table 1. Cont.
Study Animal Information Exercise Modality Chemotherapy Model Key Observations
de Lima et al.,
2020 [143]
8–10-week-old male
C57BL/6 mice with LLC
[163]
TR: F: 5 days/week, for 2–3 weeks; I: 60% of
maximal speed; D: 60 mins/day; T: 0◦ incline.
2 × IPI per week for 6 weeks of 2.5
mg/kg DOX. Harvest 24 h or
1-week post-IPI.
TR did not alter body mass, but enhanced GSN
re-growth, normalised inflammation and





mice with c26 [164]
MWR: F: once a day, with 3 days on followed
by 1 day of rest for 4 weeks; I: 11 m/min; D: 45
mins/day; T: 0◦ incline.
1 × IPI per week of OXA 6 mg/kg
and 5FU 50 mg/kg, for 3 weeks
starting at day 7 of tumour
implantation. Harvest 7 days post
final IPI.
MWR did not alter GSN mass, but normalised
atrogene expression and mitochondrial
perturbations.
Abbreviations: 5FU: 5-fluorouracil; AChR; acetylcholine receptor; c26: c26 adenocarcinoma model; CDDP: cis-diamminedichloroplatinum(II) (cisplatin); CHL: chronic hind-limb loading; CSA: cross-sectional area;
DIA: diaphragm; DOX: doxorubicin; D: duration; EDL extensor digitorum longus; F: frequency; GSN: gastrocnemius; I: intensity; IPI: intraperitoneal injection; LLC: Lewis-lung carcinoma model; MWR: motorised
wheel running; OXA: oxaliplatin; QD: quadriceps; REDD1: regulated in development and DNA damage response 1; SOL: soleus; T: type; TA: tibialis anterior; TR: treadmill running; VWR: voluntary wheel running.
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3.2. Adjuvant Therapies
Complementary to exercise strategies, several adjuvant candidates have been evalu-
ated for their protective potential to combat chemotherapy-induced cachectic myopathy.
Drug candidates focus on different biochemical targets that are involved in diverse molec-
ular and physiological aspects that characterise the cachectic myopathy phenotype [40].
These candidates arise from a range of different therapeutic classes including activin
receptor signalling inhibitors [59,60,100,103,165], appetite stimulants [77,80,82,166–170],
nutritional supplements [171–176], and phytotherapies [112,113,177–185]. Activin re-
ceptor signalling inhibitors have shown strong pre-clinical efficacy to mitigate cancer
and chemotherapy-induced cachexia through preserving skeletal muscle mass and func-
tion [186]. However, there has been limited success in the clinical translation of this
pharmacological target, with a Phase II trial conducted by Novartis Pharmaceuticals
(NCT01433263) demonstrating that activin receptor antibody, BYM338 (Bimagrumab),
improved lean mass and muscle volume, but contributed to a net loss of body mass [187].
Appetite stimulants, in particular ghrelin receptor agonists, have shown promise in
the pre-clinical setting to normalise food intake and muscle mass/CSA of chemotherapy-
treated mice compared to healthy counterparts [80,82,170]. These findings translated
clinically as observed through the ROMANA 1 & 2 trials (NCT01387269 & NCT01387282),
where anamorelin (a ghrelin receptor agonist) increased body and lean mass of advanced
cancer patients. However, it was not approved for clinical use because it failed to improve
grip strength—a primary endpoint of the trial [188].
Nutritional supplements including essential amino acids and fatty acids have shown
the capacity to protect against cancer and chemotherapy-induced cachexia, highlighting
translational potential in single supplement interventions [189]. However, nutritional
supplements are only a complementary piece of the cachexia puzzle as their clinical utility
is primarily dependent on the anabolic potential of the individual [190]. Additionally,
nutrition-related guidelines in cancer are based mostly on expert consensus, rarely on
clinical trial evidence, highlighting a greater need to investigate multi-combination nu-
tritional supplement interventions at the clinical level [191]. Similarly, compounds from
the phytotherapies class have typically not been clinically evaluated for their therapeutic
efficacy to mitigate cachectic myopathy given their rare utility in Western medicine [192].
This aspect should be re-considered based on encouraging pre-clinical data—specifically,
the reduction of atrogene transcription, which underscores skeletal muscle wasting and
holds strong promise as a therapeutic target against cachexia [193].
An emerging therapeutic class of particular interest to our laboratory group, and oth-
ers, is the utility of mitoprotective compounds to combat skeletal muscle oxidative stress.
Enhanced ROS production is a common underlying mechanism associated with multiple
chemotherapies [32,33] and is a key contributing factor to mitochondrial dysfunction, a
tenet of cachectic myopathy [36,37]. To date, mitoprotective compounds have not been
evaluated in clinical trials. However, multiple mitoprotective agents have been experi-
mentally evaluated for their potential protective efficacy against chemotherapy-induced
cachectic myopathy, which will be discussed herein.
One of the first mitoprotective agents investigated for its therapeutic efficacy alongside
chemotherapy was SS-31, a cardiolipin-targeting peptide, which preserves mitochondrial
cristae structure and promotes oxidative phosphorylation [194]. SS-31 was shown to
attenuate DOX-induced activity of multiple proteolytic systems (e.g., UPS, apoptosis,
and calpains) in various muscle types, which prevented skeletal muscle atrophy [56,68].
Further, SS-31 normalises DOX-induced ROS emission in C2C12 myotube cultures and
rodent muscle, with the latter observed as an acute event [33,56]. However, Ballaro et al.
demonstrated that SS-31 administration yielded a modest mitoprotection, and subsequently,
limited therapeutic efficacy in a more clinically compatible model of cachectic myopathy. In
this study, mice were injected with C26 colorectal adenocarcinoma cells and metronomically
dosed with OXA and 5FU combination chemotherapy over five weeks [90]. These data
highlight that SS-31 may be more efficacious at a preventative stage of cachexia (i.e.,
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pre-cachexia) when mitochondria are less damaged [131]. Alternatively, SS-31 may elicit
specific mitoprotection against the anthracycline DOX, which induces mitochondrial stress
differently to platinum-based alkylating agents, albeit this would need to be confirmed in
future studies of DOX utilising more clinically compatible models.
Another adjuvant mitoprotective agent is BGP-15, a hydroximic acid derivative nico-
tinic acid-amidoxime small molecule that can preserve skeletal muscle metabolic home-
ostasis and mitochondrial quality control processes [195,196]. In particular, BGP-15 has
been touted as an inhibitor of poly-(ADP-ribose) polymerase-1 (PARP-1) and co-inducer of
HSP-70 [197,198], which are mechanisms associated with improved mitochondrial content,
function, and oxidative capacity [199,200]. Furthermore, BGP-15 has also shown pleiotropic
capacity to elicit mitoprotection independent of these mechanisms [201], a likely explana-
tion of its therapeutic potential in a range of myopathies [202–205]. Our laboratory group
has evaluated the therapeutic utility of BGP-15 alongside multiple chemotherapies includ-
ing OXA, IRI, and 5FU with mixed efficacy [88,99,104]. BGP-15 was protective against
OXA-induced lean mass loss, while also normalising ROS generation and mitochondrial
viability [88]. However, alongside IRI, BGP-15 paradoxically rescued (partially) body, lean,
and skeletal muscle mass in addition to muscle contractile function, while exacerbating the
IRI-induced muscle protein synthesis inhibition and reduced expression of the cytoskeletal
proteins, dystrophin, and β-dystroglycan [104]. The recovery of muscle mass and function
may have been due to BGP-15′s enhancement of ATP production and mitochondrial density.
Indeed, the latter was also enhanced when BGP-15 was delivered alongside 5FU and was
associated with improved mitochondrial fusion. Furthermore, BGP-15 suppressed the
5FU-induced phosphorylation of NF-κB and MAPK isoforms [99], two likely mechanisms
involved in the induction of cachectic myopathy. Given the heterogeneity of our find-
ings, further investigations are required with a focus on clinically compatible combination
chemotherapy regimens before BGP-15 can be considered a viable therapeutic candidate to
protect against cachectic myopathy.
Future studies investigating adjuvant mitoprotective candidates should consider
agents that can synergistically target chemotherapy driven oxidative damage, alongside
other signalling pathways involved in the induction of cachectic myopathy. One potential
compound is the nuclear factor erythroid 2-related factor 2 (Nrf2) transcriptional activator,
dimethyl fumarate (DMF). DMF is a methyl ester of fumaric acid purported to upregulate
cytoprotective response genes, and suppress NF-κB signalling, which imparts an anti-
oxidative and -inflammatory effect [206] Another Nrf2 activator with therapeutic potential
in this setting could be pterostilbene [207], a dimethoxylated analogue of resveratrol, a
compound with demonstrated efficacy against DOX-mediated skeletal and cardiac my-
opathy [208,209]. Like resveratrol, pterostilbene can prolong lifespan, mitigate oxidative
stress and normalise dysregulated autophagy in experimental models [210,211]. However,
pterostilbene has greater bioavailability and a longer half-life compared to resveratrol [212],
suggesting greater translational potential. Finally, epicatechin is another potentially viable
mitoprotective candidate, which activates Nrf2 to inhibit oxidative stress [213]. Inter-
estingly, epicatechin has been shown to restore the expression of dystrophin and other
key cytoskeletal proteins in models of myopathy such as Becker muscular dystrophy
and diabetes [214,215]. This highlights the protective potential of epicatechin against the
chemotherapy-induced reduction of dystrophin expression shown by our group [99,104],
and in cancer-induced cachectic myopathy in which dystrophin is also reduced [216]. Im-
portantly, the adjuvant candidates proposed are not associated with cancer growth, and
thus are unlikely to impact the anti-cancer efficacy of chemotherapy treatment [206,217,218].
Other compounds have also been evaluated for their therapeutic efficacy against
chemotherapy-induced cachectic myopathy, whereby mitoprotection is elicited as a sec-
ondary effect to the central mechanism. Sodium nitrate (SN) supplementation is one of
these strategies. SN potentiates the nitrate/nitrite/nitric oxide (NO) pathway to increase
endogenous NO production as the central mechanism [219]. Mitoprotection occurs con-
currently via an alternate pathway [220]. SN is cardioprotective during DOX treatment
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in mice, with the preservation of left ventricular function dependent on the mitigation of
oxidative stress and mitochondrial Complex I dysfunction [221,222]. However, our eval-
uation of SN supplementation alongside DOX administration failed to elicit a protective
effect against cachectic myopathy [223]. Interestingly, the metabolic cytoprotectant, met-
formin, has also been investigated alongside DOX and demonstrated no protective benefit
against chemotherapy-induced cachectic myopathy. These drug candidates both promote
adenosine monophosphate-activated protein kinase (AMPK) signalling to preserve cellular
energy status [220,224]. Thus, they may have greater utility as a therapeutic strategy to
mitigate aberrant skeletal muscle glucose uptake during chemotherapy treatment.
4. Future Directions and Conclusions
Chemotherapy is an under-appreciated contributing factor in the induction of cachec-
tic myopathy. To date, research has predominately contextualised cancer cachexia as
governed by tumour-related factors without considering the other side of the cachexia
sphere—chemotherapy [9]. This is problematic with respect to the clinical compatibility
of this paradigm, as the large majority of cancer patients typically receive chemotherapy
as part of their treatment strategy. This highlights the need for experimental studies to
reflect the synergistic insult from cancer and chemotherapy in the induction of cachectic
myopathy [15]. Models that allow the exploration of both factors in combination, and, us-
ing the spectra of chemotherapeutic agents, multi-therapy regimens, and cancer sub-types,
are required. Future investigations in this area also need to consider the impact of novel
chemotherapeutic agents in clinical trials across all cancers. For example, the therapeutic
utility of multi-kinase inhibitors is becoming increasingly prevalent [225] and they demon-
strably have cachexia-inducing properties [226,227]. Additionally, drug compounds that
are utilised to mitigate the side-effects of clinical chemotherapy treatment such as the well-
described gastrointestinal toxicities elicited by dexamethasone [228] need to be stratified
for their capacity to potentiate chemotherapy-induced cachectic myopathy [229,230].
The utility of a cachexia scoring system within investigative animal research such as
the animal cachexia score (ACASCO) [231] is warranted to justify a relative cachectic burden
concerning chemotherapy- and cancer-induced myopathy. This will assist with the clinical
interpretation of experimental findings, and where they fit within the cachexia diagnostic
continuum in human patients, which incorporates three key stages: pre-cachexia, cachexia,
and refractory cachexia [14]. Specific to chemotherapy-induced cachectic myopathy, a
modified scoring system should also be considered to incorporate biomarkers of oxidative
stress and skeletal muscle damage, which are currently being developed for other severe
skeletal myopathies that share similar features with cachectic myopathy (i.e., dystrophin
loss and oxidative stress) as highlighted by Grounds et al. [232].
Despite emerging as a burgeoning sub-field of skeletal muscle wasting conditions,
chemotherapy-induced myopathy is, to date, a pariah with respect to research effort and
directed funding in contrast to cancer-induced myopathy [9]—comparatively, it remains
on the ‘dark side’ of the cachexia sphere. Illuminating the mechanisms involved and the
physiological repercussions as well as actively pursuing protective therapeutics will enrich
clinical decision making, patient outcomes, and the quality of cancer survivorship.
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